Since IRAK1 is a critical signaling molecule downstream of IL-1R and many TLRs, and inhibitors for IRAK1 are relatively scarce, rosoxacin may be further developed into a valuable drug for treating diseases associated with aberrant activation of various TLR pathways, such as autoimmune diseases and cancers [29]. The gene discussed is IRAK1; the disease is cancer.